1
|
Jelic S and Sotiropoulos GC: ESMO
Guidelines Working Group: Hepatocellular carcinoma: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21:v59–v64. 2010. View Article : Google Scholar
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Brabletz T, Jung A, Spaderna S, et al:
Opinion: migrating cancer stem cells - an integrated concept of
malignant tumour progression. Nat Rev Cancer. 5:744–749. 2005.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
7
|
Peinado H, Ballestar E, Esteller M and
Cano A: Snail mediates E-cadherin repression by the recruitment of
the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell
Biol. 24:306–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Jou J and Diehl AM: Epithelial-mesenchymal
transitions and hepatocarcinogenesis. J Clin Invest. 120:1031–1034.
2010. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Li X, Li P, Chang Y, et al: The
SDF-1/CXCR4 axis induces epithelial–mesenchymal transition in
hepatocellular carcinoma. Mol Cell Biochem. 392:77–84. 2014.
|
10
|
Vaupel P and Mayer A: Hypoxia in cancer:
significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lu X and Kang Y: Hypoxia and
hypoxia-inducible factors: master regulators of metastasis. Clin
Cancer Res. 16:5928–5935. 2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Dong ZZ, Yao M, Wang L, et al:
Hypoxia-inducible factor-1alpha: molecular-targeted therapy for
hepatocellular carcinoma. Mini Rev Med Chem. 13:1295–1304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Chan DA, Sutphin PD, Yen SE and Giaccia
AJ: Coordinate regulation of the oxygen-dependent degradation
domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol.
25:6415–6426. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Nyberg P, Salo T and Kalluri R: Tumor
microenvironment and angiogenesis. Front Biosci. 13:6537–6553.
2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zhao JH, Luo Y, Jiang YG, et al: Knockdown
of β-Catenin through shRNA cause a reversal of EMT and metastatic
phenotypes induced by HIF-1α. Cancer Invest. 29:377–382. 2011.
|
16
|
Singh S and Khar A: Biological effects of
curcumin and its role in cancer chemoprevention and therapy.
Anticancer Agents Med Chem. 6:259–270. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
De R, Kundu P, Swarnakar S, et al:
Antimicrobial activity of curcumin against Helicobacter
pylori isolates from India and during infections in mice.
Antimicrob Agents Chemother. 53:1592–1597. 2009.PubMed/NCBI
|
18
|
Wang J, Du XX, Jiang H and Xie JX:
Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by
anti-oxidation and nuclear factor-kappa B modulation in MES23.5
cells. Biochem Pharmacol. 78:178–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Jurenka JS: Anti-inflammatory properties
of curcumin, a major constituent of Curcuma longa: a review
of preclinical and clinical research. Altern Med Rev. 14:141–153.
2009.PubMed/NCBI
|
20
|
Kim DC, Ku SK and Bae JS: Anticoagulant
activities of curcumin and its derivative. BMB Rep. 45:221–226.
2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Olszanecki R, Jawień J, Gajda M, et al:
Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout
mice. J Physiol Pharmacol. 56:627–635. 2005.PubMed/NCBI
|
22
|
Shishodia S, Chaturvedi MM and Aggarwal
BB: Role of curcumin in cancer therapy. Curr Probl Cancer.
31:243–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Jobin C, Bradham CA, Russo MP, et al:
Curcumin blocks cytokine-mediated NF-kappa B activation and
proinflammatory gene expression by inhibiting inhibitory factor
I-kappa B kinase activity. J Immunol. 163:3474–3483.
1999.PubMed/NCBI
|
24
|
Prakobwong S, Gupta SC, Kim JH, et al:
Curcumin suppresses proliferation and induces apoptosis in human
biliary cancer cells through modulation of multiple cell signaling
pathways. Carcinogenesis. 32:1372–1380. 2011. View Article : Google Scholar
|
25
|
Yang CL, Liu YY, Ma YG, et al: Curcumin
blocks small cell lung cancer cells migration, invasion,
angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3
signalling pathway. PLoS One. 7:e379602012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Guo M, Song LP, Jiang Y, et al:
Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce
leukemic cell apoptosis through different hypoxia-inducible
factor-1alpha independent mechanisms. Apoptosis. 11:67–77. 2006.
View Article : Google Scholar
|
27
|
Li W, Ma J, Ma Q, et al: Resveratrol
inhibits the epithelial-mesenchymal transition of pancreatic cancer
cells via suppression of the PI-3K/Akt/NF-κB pathway. Curr Med
Chem. 20:4185–4194. 2013.PubMed/NCBI
|
28
|
Li X, Ma Q, Xu Q, et al: SDF-1/CXCR4
signaling induces pancreatic cancer cell invasion and
epithelial-mesenchymal transition in vitro through non-canonical
activation of Hedgehog pathway. Cancer Lett. 322:169–176. 2012.
View Article : Google Scholar
|
29
|
Han L, Peng B, Ma Q, et al: Indometacin
ameliorates high glucose-induced proliferation and invasion via
modulation of e-cadherin in pancreatic cancer cells. Curr Med Chem.
20:4142–4152. 2013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Ardyanto TD, Osaki M, Tokuyasu N, et al:
CoCl2-induced HIF-1alpha expression correlates with
proliferation and apoptosis in MKN-1 cells: a possible role for the
PI3K/Akt pathway. Int J Oncol. 29:549–555. 2006.PubMed/NCBI
|
32
|
Kew MC: Hepatocellular carcinoma in
developing countries: Prevention, diagnosis and treatment. World J
Hepatol. 4:99–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
33
|
Wu XZ, Xie GR and Chen D: Hypoxia and
hepatocellular carcinoma: The therapeutic target for hepatocellular
carcinoma. J Gastroenterol Hepatol. 22:1178–1182. 2007. View Article : Google Scholar : PubMed/NCBI
|
34
|
Anastasiadis AG, Bemis DL, Stisser BC, et
al: Tumor cell hypoxia and the hypoxia-response signaling system as
a target for prostate cancer therapy. Curr Drug Targets. 4:191–196.
2003. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kizaka-Kondoh S, Inoue M, Harada H and
Hiraoka M: Tumor hypoxia: a target for selective cancer therapy.
Cancer Sci. 94:1021–1028. 2003. View Article : Google Scholar : PubMed/NCBI
|
36
|
Yasuda H: Solid tumor physiology and
hypoxia-induced chemo/radio-resistance: novel strategy for cancer
therapy: nitric oxide donor as a therapeutic enhancer. Nitric
Oxide. 19:205–216. 2008. View Article : Google Scholar
|
37
|
Gordan JD, Bertout JA, Hu CJ, et al:
HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc
transcriptional activity. Cancer Cell. 11:335–347. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Liao D and Johnson RS: Hypoxia: a key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
39
|
Kalliomäki TM, McCallum G, Wells PG and
Hill RP: Progression and metastasis in a transgenic mouse breast
cancer model: effects of exposure to in vivo hypoxia. Cancer Lett.
282:98–108. 2009.PubMed/NCBI
|
40
|
Selvendiran K, Bratasz A, Kuppusamy ML, et
al: Hypoxia induces chemoresistance in ovarian cancer cells by
activation of signal transducer and activator of transcription 3.
Int J Cancer. 125:2198–2204. 2009. View Article : Google Scholar : PubMed/NCBI
|
41
|
Liu J, Zhang J, Wang X, et al: HIF-1 and
NDRG2 contribute to hypoxia-induced radioresistance of cervical
cancer Hela cells. Exp Cell Res. 316:1985–1993. 2010. View Article : Google Scholar : PubMed/NCBI
|
42
|
Kim Y, Lin Q, Glazer PM and Yun Z: Hypoxic
tumor microenvironment and cancer cell differentiation. Curr Mol
Med. 9:425–434. 2009. View Article : Google Scholar : PubMed/NCBI
|
43
|
Chiche J, Rouleau M, Gounon P, et al:
Hypoxic enlarged mitochondria protect cancer cells from apoptotic
stimuli. J Cell Physiol. 222:648–657. 2010.PubMed/NCBI
|
44
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
45
|
Powis G and Kirkpatrick L: Hypoxia
inducible factor-1alpha as a cancer drug target. Mol Cancer Ther.
3:647–654. 2004.PubMed/NCBI
|
46
|
Zhang Q, Bai X, Chen W, et al:
Wnt/β-catenin signaling enhances hypoxia-induced
epithelial-mesenchymal transition in hepatocellular carcinoma via
crosstalk with hif-1α signaling. Carcinogenesis. 34:962–973.
2013.
|
47
|
Xu MX, Zhao L, Deng C, et al: Curcumin
suppresses proliferation and induces apoptosis of human
hepatocellular carcinoma cells via the wnt signaling pathway. Int J
Oncol. 43:1951–1959. 2013.PubMed/NCBI
|